These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35335008)

  • 21. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil.
    Zaltman C; Parra RS; Sassaki LY; Santana GO; Ferrari MLA; Miszputen SJ; Amarante HMBS; Kaiser Junior RL; Flores C; Catapani WR; Parente JML; Bafutto M; Ramos O; Gonçalves CD; Guimaraes IM; da Rocha JJR; Feitosa MR; Feres O; Saad-Hossne R; Penna FGC; Cunha PFS; Gomes TN; Nones RB; Faria MAG; Parente MPPD; Scotton AS; Caratin RF; Senra J; Chebli JM
    World J Gastroenterol; 2021 Jan; 27(2):208-223. PubMed ID: 33510560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
    Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
    J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients.
    Azzam NA; Aljebreen A; Almuhareb A; Almadi MA
    Saudi J Gastroenterol; 2020; 26(5):256-262. PubMed ID: 32415045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic.
    Kamath C; Brenner EJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100101. PubMed ID: 35496814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study.
    Biancone L; Armuzzi A; Scribano ML; Castiglione F; D'Incà R; Orlando A; Papi C; Daperno M; Vecchi M; Riegler G; Fries W; Alvisi P; Meucci G; Mocciaro F; Rogai F; Festa S; Guidi L; Testa A; Spina L; Renna S; Viola A; Patturelli M; Di Mitri R; Frankovic I; Calabrese E; Petruzziello C; De Cristofaro E; Sena G; Ruffa A; Neri B; Rossi A
    Inflamm Bowel Dis; 2020 Feb; 26(3):450-459. PubMed ID: 31498388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
    Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
    [No Abstract]   [Full Text] [Related]  

  • 29. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
    Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
    Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.
    Rozich JJ; Dulai PS; Fumery M; Sandborn WJ; Singh S
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2437-2447.e6. PubMed ID: 32142940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helminth therapy (worms) for induction of remission in inflammatory bowel disease.
    Garg SK; Croft AM; Bager P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009400. PubMed ID: 24442917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.
    Le Berre C; Loy L; Lönnfors S; Avedano L; Piovani D
    World J Gastroenterol; 2020 Aug; 26(29):4343-4355. PubMed ID: 32848338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014.
    Ludvigsson JF; Mahl M; Sachs MC; Björk J; Michaelsson K; Ekbom A; Askling J; Backman AS; Olén O
    Am J Gastroenterol; 2019 Feb; 114(2):291-304. PubMed ID: 30730858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center.
    Szántó K; Nyári T; Bálint A; Bor R; Milassin Á; Rutka M; Fábián A; Szepes Z; Nagy F; Molnár T; Farkas K
    PLoS One; 2018; 13(7):e0200824. PubMed ID: 30059523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
    Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
    Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
    Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease.
    Benchimol EI; Carroll MW; Geist R; Griffiths AM; Huang JG; Mack DR; Bernstein CN; Bitton A; Jones JL; Kaplan GG; Kuenzig ME; Lee K; Mukhtar MS; Murthy SK; Tandon P; Targownik LE; Windsor JW; Seow CH
    J Can Assoc Gastroenterol; 2021 Dec; 4(Suppl 2):S27-S33. PubMed ID: 34755036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study.
    Losurdo G; La Fortezza RF; Iannone A; Contaldo A; Barone M; Ierardi E; Di Leo A; Principi M
    World J Gastroenterol; 2020 Dec; 26(47):7528-7537. PubMed ID: 33384552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.